Antineoplásicos/uso terapêutico; Inibidores Enzimáticos/uso terapêutico; Receptores ErbB/metabolismo; Oseltamivir/uso terapêutico; Pâncreas/efeitos dos fármacos; Neoplasias Pancreáticas/tratamento farmacológico; Transdução de Sinais/efeitos dos fármacos; Animais; Linhagem Celular Tumoral; Fator de Crescimento Epidérmico/metabolismo; Humanos; Masculino; Metaloproteinase 9 da Matriz/metabolismo; Camundongos; Células NIH 3T3; Metástase Neoplásica/prevenção & controle; Neuraminidase/metabolismo; Pâncreas/metabolismo; Pâncreas/patologia; Neoplasias Pancreáticas/metabolismo; Neoplasias Pancreáticas/patologia

0EGF; 4-MUNANA; Akt; Cγ; FGF; IC(50); MMP; Matrix metalloproteinase-9; NGF; Neu1; Neuraminidase-1; PDGF; Pancreatic cancer; RAG2; RTKs; SMAD2; STAT1; TLR; TOLL-like receptor; VEGF; [2'-(4-methylyumbelliferyl)-α-D-N-acetylneuraminic acid]; combining recombinase activating gene-2; common cytokine receptor γ chain; epidermal growth factor; fibroblast growth factor; mammalian neuraminidase-1; matrix metalloproteinase; mothers against decapentaplegic homolog-2 signal transducer and transcriptional modulator; nerve growth factor; platelet-derived growth factor; protein kinase B (PKB) a serine/threonine-specific protein kinase; receptor tyrosine kinases; signal transducer and activator of transcription-1, 91kDa; the concentration of a drug that is required for 50% inhibition in vitro; vascular endothelial growth factor